| First Author | Dai X | Year | 2023 |
| Journal | Front Immunol | Volume | 14 |
| Pages | 1239592 | PubMed ID | 37965323 |
| Mgi Jnum | J:347855 | Mgi Id | MGI:7549664 |
| Doi | 10.3389/fimmu.2023.1239592 | Citation | Dai X, et al. (2023) Myeloid Vamp3 deletion attenuates CFA-induced inflammation and pain in mice via ameliorating macrophage infiltration and inflammatory cytokine production. Front Immunol 14:1239592 |
| abstractText | Persistent inflammation and associated pain significantly impact individuals' quality of life, posing substantial healthcare challenges. Proinflammatory cytokines, released by activated macrophages, play crucial roles in the development of chronic inflammatory conditions such as rheumatoid arthritis. To identify and evaluate potential therapeutic interventions targeting this process for mitigating inflammation and pain, we created myeloid cell-specific knockout of Vamp3 (vesicle-associated membrane protein 3) mice (Vamp3 (Deltamyel)) by crossing LysM-Cre mice with newly engineered Vamp3(flox/flox) mice. Bone marrow-derived macrophages and peritoneal resident macrophages from Vamp3 (Deltamyel) mice exhibited a significant reduction in TNF-alpha and IL-6 release compared to control mice. Moreover, Vamp3 deficiency led to decreased paw edema and ankle joint swelling induced by intraplantar injection of complete Freund's adjuvant (CFA). Furthermore, Vamp3 depletion also mitigated CFA-induced mechanical allodynia and thermal hyperalgesia. Mechanistically, Vamp3 loss ameliorated the infiltration of macrophages in peripheral sites of the hind paw and resulted in reduced levels of TNF-alpha and IL-6 in the CFA-injected paw and serum. RT-qPCR analysis demonstrated downregulation of various inflammation-associated genes, including TNF-alpha, IL-6, IL-1beta, CXCL11, TIMP-1, COX-2, CD68, and CD54 in the injected paw at the test day 14 following CFA administration. These findings highlight the novel role of Vamp3 in regulating inflammatory responses and suggest it as a potential therapeutic target for the development of novel Vamp-inactivating therapeutics, with potential applications in the management of inflammatory diseases. |
